1.37

6.16% -0.09

After Hours: 1.37

RenovoRx Inc (RNXT)

Overview News Price History Financials Discussions Forecast

RenovoRx Inc stock is currently priced at $1.37, with a 24-hour trading volume of 29,072. It has seen a -6.16% decreased in the last 24 hours and a +15.13% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.43 pivot point. If it approaches the $1.36 support level, significant changes may occur.

Previous Close:

$1.46

Open:

$1.4

24h Volume:

29,072

Market Cap:

$32.81M

Revenue:

Net Income/Loss:

$-10.23M

P/E Ratio:

-1.3048

EPS:

-1.05

Net Cash Flow:

$-10.26M

1W Performance:

-5.52%

1M Performance:

+15.13%

6M Performance:

+128.33%

1Y Performance:

-34.76%

1D Range:

$1.36

$1.45

52W Range:

$0.5306

$3.29

RenovoRx Inc Stock (RNXT) Company Profile

Name

RenovoRx Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

650 284 4433

Address

4546 El Camino Real, Suite B1, Los Altos

Employee

Twitter

Next Earnings Date

2024-06-07

Latest SEC Filings

RNXT's Discussions on Twitter

RenovoRx Inc Stock (RNXT) Latest News

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024 - Business Wire

Business Wire

Biopharmaceutical Challenger Renovorx: Navigating Uncertainty and Financial Risks in Drug Development - TipRanks ... - TipRanks

TipRanks

RenovoRx (RNXT) Stock Forecast and Price Target 2024 - MarketBeat

MarketBeat

RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement - Business Wire

Business Wire

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology ... - Business Wire

Business Wire

RenovoRx Secures $11.1M Through Equity and Warrants Offering - TipRanks.com - TipRanks

TipRanks

RenovoRx Inc Stock (RNXT) Financials Data

RenovoRx Inc (RNXT) Net Income 2024

RNXT net income (TTM) was -$10.23 million for the quarter ending December 31, 2023, a -3.47% decrease year-over-year.

RenovoRx Inc (RNXT) Cash Flow 2024

RNXT recorded a free cash flow (TTM) of -$10.26 million for the quarter ending December 31, 2023, a -16.42% decrease year-over-year.

RenovoRx Inc (RNXT) Earnings per Share 2024

RNXT earnings per share (TTM) was -$1.01 for the quarter ending December 31, 2023, a +7.34% growth year-over-year.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.